Tag: Shockwave

Johnson & Johnson Confirms Durability of IVL in Complex, Below-the-Knee Anatomy in Late-Breaking Presentation at VIVA 2025

DISRUPT BTK II one-year outcomes data demonstrate the strong safety profile and consistent effectiveness of the Shockwave Peripheral IVL system to help support  wound healing and limb preservation LAS VEGAS, November 3, 2025 – Johnson & Johnson MedTech, a global leader in the field of circulatory restoration, today announced the one-year results […]

Johnson & Johnson Announces Launch of its Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter in Europe to Transform Treatment of Difficult-to-Cross Calcified Lesions

  SANTA CLARA, Calif. – September 15, 2025 – Today, Johnson & Johnson announced the European launch of its Shockwave Javelin Peripheral IVL Catheter, a novel intravascular lithotripsy (IVL) platform designed to modify calcium in extremely narrowed vessels to expand treatments in patients suffering from peripheral artery disease (PAD). The first-of-its-kind Forward IVL […]

Shockwave Medical Study Confirms Benefit of IVL-First Strategy in Real-World Female Patients with Complex Calcified Lesions in Late-Breaking Data Presentation at EuroPCR 2025

EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools PARIS, May 20, 2025 /PRNewswire/ — Shockwave Medical, Inc., part of Johnson & Johnson MedTech and a global…

Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified Lesions

Now available in the U.S., the Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter safely modifies and crosses occlusive or extremely narrowed calcific peripheral artery disease SANTA CLARA, Calif., March 4, 2025 /PRNewswire/ — Today, Shockwave Medical, Inc., part of Johnson…

Shockwave Medical Reports Second Quarter 2023 Financial Results

SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023. Recent Highlights Recognized revenue of $180.2 million for […]

Shockwave Medical Announces Details for Conference Call Discussing Second Quarter 2023 Results and Participation in Upcoming Investor Conference

SANTA CLARA, Calif., July 18, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the second quarter 2023 after market close on Monday, August 7, 2023. Company management will host […]

Shockwave Medical Launches New Coronary IVL Catheter Internationally and Enrolls First Patient in All-Female Empower Study

Shockwave C2+ Catheter Expands Utility of IVL in Calcified Coronary Arteries SANTA CLARA, Calif., May 15, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced the full commercial availability of the Shockwave C2+ Coronary […]

Shockwave Medical Reports First Quarter 2023 Financial Results

SANTA CLARA, Calif., May 08, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023. Recent Highlights Recognized revenue of $161.1 million […]